VJHemOnc Podcast

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting. In this podcast, Rob...

Myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases which remain a challenge to treat, and immune dysregulation has been found to play a key role in the pathogenesis of MDS. There is a growing interest, by researchers, as well as clinicians, to better understand the role of the innate immune system in this disease, and further investigate novel agents and strategies to trea...

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting. The first session fr...

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year's meeting. The first session from iwNHL focused on advances in the treatment and man...

The 18th Meeting of the International Society of Amyloidosis (ISA) was held in Heidelberg, Germany, on 4-8 September, 2022. This meeting brought together experts in amyloidosis as they discussed the latest updates in the field, including novel therapeutic approaches, clinical trial updates, and recent advances in the diagnosis and management of this disease. In this exclusive podcast, you will hea...

The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, CA, and brought together experts in the field, who discussed several fascinating topics, including novel treatment strategies in multiple myeloma, the prognostic value of measurable residual disease (MRD), managing patients with high-risk disease, and more.  In this exclusive podcast, Charlotte Pawlyn, BA, MBBChir...

The 2022 Texas MPN Workshop was held in San Antonio, TX, and covered several fascinating topics in the field of myeloproliferative neoplasms (MPNs). MPNs represent a heterogeneous group of diseases that remain a challenge to diagnose and treat. Several experts agree that early intervention and better understanding disease progression are crucial aspects to consider when treating patients, and stud...

The 1st International Workshop on Myelodysplastic Syndromes (iwMDS) 2022 was held in Miami, FL, and brought together leading experts in MDS who discussed the latest updates in the field. Several fascinating topics were covered at this year's meeting, including immune dysregulation and targeting in MDS, improving the efficiency of drug approvals, treating high-risk disease, and more.  In this podca...

Multiple myeloma is a heterogeneous disease, and despite recent advances in therapeutic agents, several patients still relapse after therapy and have poor survival outcomes. The identification of high-risk features, including the presence of del(17p) and t(4;14), are crucial for improving diagnosis and outcomes for these patients.  In this podcast, Heinz Ludwig, MD, Wilhelminen Cancer Research Ins...

In recent years, the treatment and management of myelodysplastic syndromes (MDS) has improved, and several clinical trials are investigating novel combinations and agents with the aim of providing more options for patients. Due to the heterogeneity of this disease, there are several challenges with treating MDS, and a need to improve the availability of therapeutic agents. In this podcast, leading...

Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have been made in recent years, both in the diagnosis and treatment of MPNs. The 2022 Annual Texas MPN Workshop brought together leading experts in the field, who discussed current and future treatment strategies, ongoing clinical trials, and future outlooks....

The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early diagnosis and intervention are important factors in MDS. Several experts agree that there is a need to develop more effective first-line therapies, and numerous clinical trials are exploring novel agents and combinations that may improve patient outcomes. In this e...

There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that were covered include: the role of genomics in the age of immuno-oncology, novel targets and agents, T-cell engagers, and resistance to immunotherapies.  In this podcast, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York, NY, Rafael Fonseca, MD, Mayo C...

The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents, including Bruton's tyrosine kinase (BTK) inhibitors, the BCL-2 inhibitor venetoclax, and anti-CD20 antibodies. CAR-T cell therapy has also improved treatment options for patients with various other hematological malignancies, although there are several barri...

The relationship between mutations and precursor states in myelodysplastic syndromes (MDS) is a growing area of research, and advances in next-generation sequencing (NGS) have allowed experts to gain a better understanding of pre-MDS states. Early detection of precursor conditions, including clonal cytopenia of undetermined significance (CCUS) and clonal hematopoiesis of indeterminate potential (C...

Several novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of this disease. However, relapse is still common in many patients, and there is a need to continue exploring novel therapeutic strategies. The introduction of immunotherapies, including CAR-T cell therapy and bispecific T-cell engagers, has marked a paradigm shift in the t...

Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms, and the treatment and management of high-risk MDS remains a challenge. With only two agents currently approved by the FDA and available to patients with high-risk disease, several experts agree that novel therapeutic strategies should be explored. Many ongoing clinical trials are evaluating the safety and efficac...

CAR-T therapies have been approved for use in several hematological malignancies, and have greatly improved treatment options for patients, especially those with relapsed disease. While CAR-T products provide many benefits, it is also important to better understand the impact of these therapies on quality of life (QoL), including adverse events such as cytokine release syndrome (CRS) and neurotoxi...

CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable data on the safety and efficacy of these agents. At the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL, several fascinating sessions took place, where leading experts discussed the application and challenges of CAR-T thera...

Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While the treatment landscape of AML has improved in recent years due to advances in therapy, there are still several hurdles to overcome to improve the efficacy of these novel agents. In this podcast, you will hear from leading experts John DiPersio, MD,...

Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), and several clinical trials have demonstrated the efficacy of CAR-Ts in this field. Experts are also debating the possibility of bringing CAR-T therapy into earlier lines of treatment, and ongoing clinical trials are...

While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years. Novel immunotherapies, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), continue to transform the myeloma treatment landscape and provide patients with more hope. At the 2022 EHA Annual Meeting, there were several exciting updates presente...

Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years, the gold standard for assessing disease risk has been the Revised International Prognostic Scoring System (IPSS-R). However, the recently-developed IPSS-Molecular (IPSS-M) has been evaluated and provides valuable information, improving overall risk a...

At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety of topics, including novel targets, T-cell engager therapy, myeloma at the single-cell level, the role of measurable residual disease (MRD), and more. Leading experts came together to discuss, debate, and answer questions, bringing you the latest in the field. In this excl...

Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in the development of this disease and progression to acute myeloid leukemia (AML). Several novel targets are being explored in this field with the aim of increasing treatment options for patients and improving response to therapies.  In this exclusive podcast,...